Table 3 Baseline information of NSCLC patients with EGFR mutation
Clinical factors | Patients (%) | Death | Log-rank test, p |
|---|---|---|---|
Age | |||
  > =65 | 24 (53.3%) | 14 | 0.70 |
  < 65 | 21 (46.7%) | 9 |  |
Gender | |||
 Male | 13 (28.9%) | 7 | 0.6 |
 Female | 32 (71.1%) | 16 |  |
Race | |||
 Asian | 2 (4.4%) | 1 | 0.6 |
 Black or African American | 3 (6.7%) | 1 |  |
 Not reported | 4 (8.9%) | 1 |  |
 White | 36 (80.0%) | 20 |  |
Cancer Status | |||
 Tumor free | 20 (44.4%) | 6 | 0.01* |
 With tumor | 15 (33.3%) | 12 |  |
 Unknow | 10 (22.2) | 5 |  |
Stage | |||
 Stage I | 22 (48.9%) | 9 | 0.6 |
 Stage II | 9 (20.0%) | 5 |  |
 Stage III | 11 (24.4%) | 8 |  |
 Stage IV | 2 (4.4%) | 1 |  |
 Not reported | 1 (2.2%) | 0 |  |